Recombinant anti-human interleukin-6 antibody (clone 2A10)

Catalogue #

R1-640-100

Name

Recombinant anti-human interleukin-6 antibody (clone 2A10)

Target

Recombinant hIL-6 protein

Target Description

Recombinant human IL-6 protein produced by CHO-based Icosagen Cell factory Ltd. proprietary suspension cell line.

Alternative Names

Interleukin-6, IL6, IL-6, B-cell stimulatory factor 2, BSF-2, CTL differentiation factor, CDF, interferon beta-2, IFN-beta-2

Uniprot ID

P05231

Clonality

Human monoclonal

Clone

2A10

Class

hIgG1

Reactivity

Reacts with human IL-6.
No cross-reactivity with IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-8, IFNγ and TNFα proteins.

Dissociation constant (K_D)

Summary of antibody screening to soluble IL-6 antigen using an Octet system.
KD, M: 3,96E-09

Application

ELISA, CLIA

Protocol

Purification

Protein A affinity chromatography followed by desalting

Concentration

1 mg/ml

Buffer

PBS pH 7.4

QC

Simply Blue Safe stained SDS-PAGE, analytical SEC, Octet BLI analysis

Related Products

IL-6 antibody clone 2A10 has been identified as a recommended detection antibody with clone 14E2 (cat# R1-648-100) and clone 12C1 (cat# R1-646-100).

Shipping

Shipped on dry ice.

Storage

Store in -65...-85 °C. Avoid multiple freeze-thaw cycles.

Background

Human interleukin-6 (IL-6) is a cytokine secreted by a broad spectrum of cells such as innate immune cells, B cells, endothelial cells, fibroblasts, astrocytes, epithelial cells, and several malignant cells. It is produced in response to tissue damage or environmental stress, microbial products, viruses or other proinflammatory cytokines. IL-6 is involved in a variety of physiological processes, including the regulation of immune response, inflammation, metabolism, bone metabolism, cancer development and progression. Elevated IL-6 concentrations are associated with several inflammatory diseases and malignancies, e.g., multiple myeloma, rheumatoid arthritis, Crohn’s disease, cardiovascular diseases and osteoporosis. In addition, increased levels of IL-6 have been observed in severe cases of COVID-19. Therefore, monitoring IL-6 levels may provide useful information for disease prognosis and management.